Amber D. Horbath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amber D. Horbath has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Boyi Gan
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
19 shared publications - Guang Lei
Furong Laboratory, Central South University, Changsha, China
18 shared publications - Xiaoguang Liu
Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education) of the Second Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China
18 shared publications - Hyemin Lee
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
16 shared publications - Yuelong Yan
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
16 shared publications - Chao Mao
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
15 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Table S1 shows relative IC50 of RSL3, ML210, JKE-1674, or ML162 in the indicated cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Table S1 shows relative IC50 of RSL3, ML210, JKE-1674, or ML162 in the indicated cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S7 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Figure S1 shows that BRCA1 deficiency promotes GPX4i–induced ferroptosis. Supplementary Figure S2 shows that BRCA1 regulates GPX4 through the BRCT domain. Supplementary Figure S3 shows that BRCA1 deficiency suppresses erastin-induced ferroptosis via interference with VDAC3 transcription and mitochondrial lipid peroxidation.Supplementary Figure S4 shows that PARPi synergize with GPX4i in BRCA1-deficient cancers via ferroptosis. Supplementary Figure S5 shows that PARPi combined with GPX4i in BRCA1-mutant/deficient or homologous-recombination-restored cells or tumors. Supplementary Figure S6 shows that NCOA4-mediated ferritinophagy coupled with defective GPX4 induction contributes to the synergy of PARPi and GPX4i in BRCA1-deficient cancer cells. Supplementary Figure S7 shows that GPX4i overcome resistance to PARPi in BRCA1-mutant tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S7 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Figure S1 shows that BRCA1 deficiency promotes GPX4i–induced ferroptosis. Supplementary Figure S2 shows that BRCA1 regulates GPX4 through the BRCT domain. Supplementary Figure S3 shows that BRCA1 deficiency suppresses erastin-induced ferroptosis via interference with VDAC3 transcription and mitochondrial lipid peroxidation.Supplementary Figure S4 shows that PARPi synergize with GPX4i in BRCA1-deficient cancers via ferroptosis. Supplementary Figure S5 shows that PARPi combined with GPX4i in BRCA1-mutant/deficient or homologous-recombination-restored cells or tumors. Supplementary Figure S6 shows that NCOA4-mediated ferritinophagy coupled with defective GPX4 induction contributes to the synergy of PARPi and GPX4i in BRCA1-deficient cancer cells. Supplementary Figure S7 shows that GPX4i overcome resistance to PARPi in BRCA1-mutant tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary table S2 shows relevant gene mutation information for the cell lines and xenografts
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary table S2 shows relevant gene mutation information for the cell lines and xenografts
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Table S3 shows sgRNA oligos sequences and primer sequences
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Table S3 shows sgRNA oligos sequences and primer sequences
- Open Access
- 2 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Table S1 shows relative IC50 of RSL3, ML210, JKE-1674, or ML162 in the indicated cells.
- 2 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Table S1 shows relative IC50 of RSL3, ML210, JKE-1674, or ML162 in the indicated cells.
- Open Access
- 2 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Table S3 shows sgRNA oligos sequences and primer sequences
- 2 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Table S3 shows sgRNA oligos sequences and primer sequences
- Open Access
- 2 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Table S1 shows relative IC50 of RSL3, ML210, JKE-1674, or ML162 in the indicated cells.
- 2 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Table S1 shows relative IC50 of RSL3, ML210, JKE-1674, or ML162 in the indicated cells.
- Open Access
- 2 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary table S2 shows relevant gene mutation information for the cell lines and xenografts
- 2 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary table S2 shows relevant gene mutation information for the cell lines and xenografts
- Open Access
- 2 August 2024
- Published by American Association for Cancer Research (AACR)
Data from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Resistance to poly (ADP-ribose) polymerase inhibitors (PARPi) limits the therapeutic efficacy of PARP inhibition in treating breast cancer susceptibility gene 1 (BRCA1)-deficient cancers. Here we reveal that BRCA1 has a dual role in regulating ferroptosis. BRCA1 promotes the transcription of voltage-dependent anion channel 3 (VDAC3) and glutathione peroxidase 4 (GPX4); consequently, BRCA1 deficiency promotes cellular resistance to erastin-induced ferroptosis but sensitizes cancer cells to ferroptosis induced by GPX4 inhibitors (GPX4i). In addition, nuclear receptor coactivator 4 (NCOA4)-mediated ferritinophagy and defective GPX4 induction unleash potent ferroptosis in BRCA1-deficient cancer cells upon PARPi and GPX4i co-treatment. Finally, we show that xenograft tumors derived from patients with BRCA1-mutant breast cancer with PARPi resistance exhibit decreased GPX4 expression and high sensitivity to PARP and GPX4 co-inhibition. Our results show that BRCA1 deficiency induces a ferroptosis vulnerability to PARP and GPX4 co-inhibition and inform a therapeutic strategy for overcoming PARPi resistance in BRCA1-deficient cancers.Significance:BRCA1 deficiency promotes resistance to erastin-induced ferroptosis via blocking VDAC3 yet renders cancer cells vulnerable to GPX4i-induced ferroptosis via inhibiting GPX4. NCOA4 induction and defective GPX4 further synergizes GPX4i with PARPi to induce ferroptosis in BRCA1-deficient cancers and targeting GPX4 mitigates PARPi resistance in those cancers.See related commentary by Alborzinia and Friedmann Angeli, p. 1372
- 2 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Resistance to poly (ADP-ribose) polymerase inhibitors (PARPi) limits the therapeutic efficacy of PARP inhibition in treating breast cancer susceptibility gene 1 (BRCA1)-deficient cancers. Here we reveal that BRCA1 has a dual role in regulating ferroptosis. BRCA1 promotes the transcription of voltage-dependent anion channel 3 (VDAC3) and glutathione peroxidase 4 (GPX4); consequently, BRCA1 deficiency promotes cellular resistance to erastin-induced ferroptosis but sensitizes cancer cells to ferroptosis induced by GPX4 inhibitors (GPX4i). In addition, nuclear receptor coactivator 4 (NCOA4)-mediated ferritinophagy and defective GPX4 induction unleash potent ferroptosis in BRCA1-deficient cancer cells upon PARPi and GPX4i co-treatment. Finally, we show that xenograft tumors derived from patients with BRCA1-mutant breast cancer with PARPi resistance exhibit decreased GPX4 expression and high sensitivity to PARP and GPX4 co-inhibition. Our results show that BRCA1 deficiency induces a ferroptosis vulnerability to PARP and GPX4 co-inhibition and inform a therapeutic strategy for overcoming PARPi resistance in BRCA1-deficient cancers.Significance:BRCA1 deficiency promotes resistance to erastin-induced ferroptosis via blocking VDAC3 yet renders cancer cells vulnerable to GPX4i-induced ferroptosis via inhibiting GPX4. NCOA4 induction and defective GPX4 further synergizes GPX4i with PARPi to induce ferroptosis in BRCA1-deficient cancers and targeting GPX4 mitigates PARPi resistance in those cancers.See related commentary by Alborzinia and Friedmann Angeli, p. 1372
- Open Access
- 2 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Table S3 shows sgRNA oligos sequences and primer sequences
- 2 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Table S3 shows sgRNA oligos sequences and primer sequences